Medinice S.A (ICE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medinice S.A (ICE) has a cash flow conversion efficiency ratio of -0.020x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-1.77 Million ≈ $-487.13K USD) by net assets (zł88.12 Million ≈ $24.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Medinice S.A (ICE) market capitalisation for the company's overall valuation and market capitalisation.
Medinice S.A - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Medinice S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Medinice S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medinice S.A ranked by their cash flow conversion efficiency. Explore earnings quality score of Medinice S.A to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Private Equity Holding AG
SW:PEHN
|
0.010x |
|
Rav Bariach 08 Industries Ltd
TA:BRIH
|
0.076x |
|
Bhartiya International Limited
NSE:BIL
|
0.056x |
|
msg life ag
HM:MSGL
|
-0.019x |
|
Corbus Pharmaceuticals Holding
NASDAQ:CRBP
|
-0.290x |
|
Plenitude Bhd
KLSE:5075
|
0.038x |
|
Tonix Pharmaceuticals Holding Corp
NASDAQ:TNXP
|
-0.162x |
|
Admicom Oyj
HE:ADMCM
|
0.050x |
Annual Cash Flow Conversion Efficiency for Medinice S.A (2016–2025)
The table below shows the annual cash flow conversion efficiency of Medinice S.A from 2016 to 2025. View ICE live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | zł88.12 Million ≈ $24.25 Million |
zł-5.58 Million ≈ $-1.54 Million |
-0.063x | -40.47% |
| 2024-12-31 | zł81.01 Million ≈ $22.30 Million |
zł-3.65 Million ≈ $-1.01 Million |
-0.045x | +56.60% |
| 2023-12-31 | zł33.17 Million ≈ $9.13 Million |
zł-3.45 Million ≈ $-948.66K |
-0.104x | -38.40% |
| 2022-12-31 | zł37.13 Million ≈ $10.22 Million |
zł-2.79 Million ≈ $-767.30K |
-0.075x | -81.17% |
| 2021-12-31 | zł40.58 Million ≈ $11.17 Million |
zł-1.68 Million ≈ $-462.91K |
-0.041x | +78.44% |
| 2020-12-31 | zł16.98 Million ≈ $4.67 Million |
zł-3.26 Million ≈ $-898.30K |
-0.192x | +69.21% |
| 2019-12-31 | zł8.23 Million ≈ $2.26 Million |
zł-5.14 Million ≈ $-1.41 Million |
-0.624x | +3.90% |
| 2018-12-31 | zł2.92 Million ≈ $802.27K |
zł-1.89 Million ≈ $-521.27K |
-0.650x | -25.07% |
| 2017-12-31 | zł3.26 Million ≈ $898.55K |
zł-1.70 Million ≈ $-466.80K |
-0.520x | +87.38% |
| 2016-12-31 | zł151.95K ≈ $41.82K |
zł-625.36K ≈ $-172.11K |
-4.116x | -- |
About Medinice S.A
Medinice S.A., a medical technology company, creates, develops, and commercializes minimally invasive solutions in cardiology and cardiac surgery. The company offers PacePress, a medical device to reduce the risk of complications following the implantation of cardiac electrotherapeutic devices, such as pacemakers or implantable cardioverter-defibrillators; CoolCryo, a cardiac cryoablation technol… Read more